12,015 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by LM Advisors LLC

LM Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, HoldingsChannel reports. The fund bought 12,015 shares of the biopharmaceutical company’s stock, valued at approximately $1,110,000.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. Howe & Rusling Inc. grew its stake in Gilead Sciences by 2.5% during the 4th quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 115 shares during the last quarter. NEOS Investment Management LLC boosted its holdings in Gilead Sciences by 35.5% in the fourth quarter. NEOS Investment Management LLC now owns 205,829 shares of the biopharmaceutical company’s stock worth $19,012,000 after acquiring an additional 53,891 shares in the last quarter. UniSuper Management Pty Ltd grew its stake in shares of Gilead Sciences by 79.2% during the fourth quarter. UniSuper Management Pty Ltd now owns 410,659 shares of the biopharmaceutical company’s stock worth $37,933,000 after acquiring an additional 181,510 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $362,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Gilead Sciences by 8.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,056,190 shares of the biopharmaceutical company’s stock valued at $187,956,000 after purchasing an additional 166,474 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 1.3 %

GILD stock opened at $109.27 on Thursday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a 50-day simple moving average of $104.69 and a 200-day simple moving average of $94.46. The stock has a market capitalization of $136.08 billion, a P/E ratio of 295.32, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.89%. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent analyst reports. Morgan Stanley upped their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, March 11th. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Royal Bank of Canada boosted their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Bank of America raised their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Finally, JPMorgan Chase & Co. upped their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $104.52.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 302,785 shares of company stock worth $30,503,250 over the last three months. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.